Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies.

作者
Kim N. Chi,Fred Saad C,Simon Chowdhury,Julie Nicole Graff,Neeraj Agarwal,Stéphane Marie. Oudard,Gang Li,Angela Mennicke Lopez- Gitlitz,Julie S. Larsen,Sharon Anne McCarthy,Suneel Dinkar Mundle,Matthew Raymond Smith,Eric Jay Small
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (15_suppl): 5541-5541 被引量:8
标识
DOI:10.1200/jco.2020.38.15_suppl.5541
摘要

5541 Background: The phase III TITAN and SPARTAN studies demonstrated improved outcomes with the addition of apalutamide (APA) to androgen deprivation therapy (ADT); outcomes included prolonging overall survival and radiographic progression-free survival (rPFS) in metastatic castration-sensitive prostate cancer (mCSPC) in TITAN, and metastasis-free survival (MFS) in nonmetastatic castration-resistant PC (nmCRPC) in SPARTAN. A post hoc analysis of PSA kinetics in pts from both studies is reported. Methods: Baseline PSA at randomization, time to PSA nadir, and proportion of pts achieving a PSA decline of ≥ 90% (PSA90) and of pts achieving a PSA ≤ 0.2 ng/mL at 3 and 12 months and at any time after treatment in the APA arms of the TITAN and SPARTAN studies were evaluated. Within each study, rPFS/MFS were compared between pts achieving a PSA90 or PSA ≤ 0.2 ng/mL response vs not. Results: 525 TITAN pts and 806 SPARTAN pts treated with APA were included in the analysis. Median baseline PSA, time to PSA nadir, median PSA nadir, and maximum percentage changes from baseline PSA are shown in the table. PSA90 and confirmed PSA ≤ 0.2 ng/mL were evident as early as 3 months in both TITAN and SPARTAN, and percentage of confirmed response continued to increase at 12 months. Pts treated with APA who achieved PSA90 were at lower risk of rPFS events in TITAN and of MFS events in SPARTAN, with a hazard ratio (95% confidence interval) of 0.46 (0.321-0.653) and 0.36 (0.271-0.489) in each respective study (both p < 0.0001), compared with APA pts who did not achieve PSA90. Pts with confirmed PSA ≤ 0.2 ng/mL had similar rPFS and MFS benefits. Conclusions: Pts with advanced PC, whether mCSPC or nmCRPC, treated with APA + ADT demonstrated rapid PSA declines that continued over time. There was a high rate of pts with PSA90 and with PSA ≤ 0.2 ng/mL responses, with a majority of pts reaching PSA90 by 12 months. Pts achieving PSA90 and/or PSA nadir of ≤ 0.2 ng/mL had a prolonged rPFS and MFS in TITAN and SPARTAN, respectively. Clinical trial information: NCT02489318; NCT01946204 . [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lion完成签到,获得积分10
1秒前
1秒前
613完成签到 ,获得积分10
3秒前
lzl007完成签到 ,获得积分0
3秒前
lxg完成签到 ,获得积分10
4秒前
恒驰完成签到,获得积分10
5秒前
汉堡包的应助被吴旭东采纳,获得10
7秒前
负责谷秋完成签到 ,获得积分10
8秒前
温暖的雪萍完成签到,获得积分10
8秒前
长情的向真完成签到 ,获得积分10
8秒前
体贴凌寒完成签到 ,获得积分10
8秒前
wei完成签到 ,获得积分10
9秒前
神勇雪瑶完成签到,获得积分10
11秒前
嵩嵩常安完成签到 ,获得积分10
13秒前
13秒前
夏天完成签到 ,获得积分10
14秒前
任伟超完成签到,获得积分10
14秒前
Cly940815完成签到,获得积分10
14秒前
15秒前
来都来了完成签到 ,获得积分10
16秒前
16秒前
笨笨水儿完成签到 ,获得积分10
16秒前
shouyu29发布了新的文献求助10
19秒前
曼曼完成签到,获得积分10
19秒前
Shuaiyang完成签到 ,获得积分10
20秒前
蝈蝈完成签到,获得积分10
20秒前
吴旭东发布了新的文献求助10
21秒前
勾陈一完成签到,获得积分10
21秒前
周巍完成签到 ,获得积分10
22秒前
雨恋凡尘完成签到,获得积分0
22秒前
研友_LMpo68完成签到 ,获得积分10
23秒前
QAQSS完成签到 ,获得积分10
24秒前
25秒前
麒麟发布了新的文献求助20
25秒前
俭朴觅松完成签到 ,获得积分10
26秒前
打打的应助被薯片采纳,获得10
27秒前
jenny完成签到,获得积分10
28秒前
泥泥完成签到 ,获得积分10
28秒前
英俊安蕾完成签到,获得积分10
29秒前
Joy完成签到,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173350
求助须知:如何正确求助?哪些是违规求助? 9565632
关于积分的说明 21780706
捐赠科研通 7767517
什么是DOI,文献DOI怎么找? 3431557
关于科研通互助平台的介绍 2555846
邀请新用户注册赠送积分活动 2476749